Treatment with the agonistic TREM2 antibody 4D9 leads to the formation of smaller necrotic cores (red outlines) in atherosclerotic plaques of the aortic root in Ldlr-/- mice. © Nature Cardiovascular Research

TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.

Picture: ©?Barbara Evripidou FirstAvenuePhotography.com

As cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is fit for the future – helping satisfy the growing demand for meat while boosting food security – but political opposition has mounted, with the Italian government taking the controversial step of banning cultivated meat.

Boehringer's broad commercial expertise and development capabilities cover the whole value chain. © Boehringer

The world of microbial product manufacturing is a complex landscape, ­driven by a diverse range of molecule formats and manufacturing processes. At the forefront of this specialty market is Boehringer Ingelheim Vienna, one global leader in biopharmaceutical development and manufacturing.

Kilger_Ute_im_Raum_small_sw_IP

In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?

© Stephanie Kath-Schorr

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.

© SynaptixBio Ltd

Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.

Picture: AAX Biotech

Swedish biotech startup AAX Biotech strengthens the management team with the appointment of Juan Astorga-Wells. He became new Senior Manager of Science & Development.

Pieere Fabre' R&D centre at Oncopole in Toulouse. © Par Don-vip - wikipedia.org

Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.

Image by Freepik

PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, focusing on the development of non-viral gene therapies coupled with minimally-invasive delivery technology.

LimmaTech Biologics is based in the Bio-Technopark Schlieren-Zurich. © Limmatstadt AG

Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).